TOPLINE: Four clinical organizations jointly released a clinical advisory with evidence-based nutrition and lifestyle interventions to enhance glucagon-like peptide 1 (GLP-1) treatment outcomes for obesity. METHODOLOGY: An expert group comprised of multiple clinical and research disciplines assessed the literature to identify pragmatic priorities for nutrition and other lifestyle interventions relevant to GLP-1 treatment for obesity. … Read more
Archyde Cannabis Use Surges among Older Adults in The U.S., Raising Concerns Among Experts Washington, D.C. – Recent data indicates a notable rise in cannabis use among older adults in the United States, especially in states where medical cannabis is legal. This trend has sparked concerns among researchers and healthcare professionals, who point to potential … Read more
Cannabis use in older adults is up, according to researchers who used a national survey database to study emergent patterns in older adult use of the substance. Their results were published online in JAMA Internal Medicine. After noting an upward trend in seniors using cannabis — from 1.0% in 2005 to 4.2% in 2018 — … Read more
With the explosive popularity of glucagon-like peptide 1 (GLP-1) agonists, physicians say a key avenue in treating obesity is being underutilized by many clinicians: First-generation anti-obesity medications (AOMs). “First-generation medications don’t get as much attention as the newer ones,” said Courtney Younglove, MD, an obesity specialist and founder of Heartland Weight Loss in Overland Park, … Read more
LOS ANGELES — The novel phosphodiesterase 10A (PDE10A) inhibitor known as CPL’36 (Celon Pharma) is effective and generally safe in acute exacerbations of schizophrenia, new research suggested. In a phase 2 trial of 189 patients with acute schizophrenia, compared with the placebo group, the groups receiving CPL’36 20 or 40 mg once daily both met … Read more
LOS ANGELES — Saffron may help treat sexual dysfunction related to selective serotonin reuptake inhibitors (SSRIs), new research suggests. Results of a preliminary new review found saffron, a spice derived from the flower of Crocus sativus, commonly known as the “saffron crocus,” reduced erectile dysfunction in men and boosted arousal in women. Jeremy Wolfe, MD … Read more
Primary care practices are seeing an uptick in patients inquiring about glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications due to both media hype and sizzle-reel stories they see on social media. If your patients start an appointment with their own agenda about wanting a prescription for these medications, there are ways to pause the … Read more
Patients with early Alzheimer’s disease (AD) who initiated lecanemab treatment at a specialty memory clinic showed an expected and manageable side-effect profile, new research showed. “The findings are very reassuring,” Barbara Joy Snider, MD, PhD, professor of neurology, and director of the Memory Diagnostic Center and Knight ADRC Clinical Trials Unit, Washington University School of … Read more
A new systematic review and network meta-analysis showed few differences in the cardiovascular (CV) effects of stimulants and noradrenaline reuptake inhibitors used to treat attention-deficit/hyperactivity disorder (ADHD). Short-term use of amphetamines, atomoxetine, lisdexamfetamine, methylphenidate, and viloxazine was associated with small increases in blood pressure (BP), pulse, or both in children, adolescents, and adults. Further, the … Read more
A new social media trend is making headlines: Methylene blue is being touted as a cognitive booster and antiaging miracle. Influencers such as Ben Greenfield are promoting the use of this chemical to enhance brain performance, strengthen the immune system, and even prevent cancer without providing scientific evidence. Researchers have warned that methylene blue can … Read more